Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ARTIVION, INC.

Get SEC filing alerts via email and in your feed for ARTIVION, INC.

AORT

ARTIVION, INC.

About ARTIVION, INC.

Artivion, Inc. is a medical device company specializing in cardiac and vascular surgical solutions for aortic disease. Its key products include aortic stent grafts, On-X mechanical heart valves, and surgical sealants like BioGlue. With a focus on innovation and global expansion, Artivion targets cardiac and vascular surgeons. The company is pursuing new product development and regulatory approvals, enhancing its market presence in emerging regions like China and Brazil.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ARTIVION, INC.

1
1
ARTIVION, INC. Artivion Reports 18% Revenue Growth to $116.3 Million in Q1 2026

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
ARTIVION, INC. Artivion Reports 14% Revenue Growth to $441.3 Million for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ARTIVION, INC. Artivion Reports 18% Revenue Growth to $113.4 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ARTIVION, INC. Artivion Reports 15% Revenue Growth to $113M in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ARTIVION, INC. Artivion Reports $98.978 Million Revenue in Q1 2025, Faces Net Loss and Increased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ARTIVION, INC. Artivion Reports $388.5 Million Revenue for Fiscal Year 2024, Net Loss Improves

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ARTIVION, INC. Artivion Reports 9% Revenue Growth, Improved Margins, and Turnaround in Q3 2024 Results

Via official filing (AI summary) | over 1 year ago | 0 comments